Статті в журналах з теми "Eribulin Mesylate"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Eribulin Mesylate".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Huyck, Timothy K., William Gradishar, Fil Manuguid, and Peter Kirkpatrick. "Eribulin mesylate." Nature Reviews Drug Discovery 10, no. 3 (March 2011): 173–74. http://dx.doi.org/10.1038/nrd3389.
Повний текст джерелаJain, Sarika, and Linda T. Vahdat. "Eribulin Mesylate." Clinical Cancer Research 17, no. 21 (August 22, 2011): 6615–22. http://dx.doi.org/10.1158/1078-0432.ccr-11-1807.
Повний текст джерелаEdwards, Michael S., Dominic A. Solimando, and J. Aubrey Waddell. "Eribulin Mesylate and Denosumab." Hospital Pharmacy 46, no. 4 (April 2011): 247–53. http://dx.doi.org/10.1310/hpj4604-247.
Повний текст джерелаVerdaguer, Helena, Idoia Morilla, and Ander Urruticoechea. "Eribulin Mesylate in Breast Cancer." Women's Health 9, no. 6 (November 2013): 517–26. http://dx.doi.org/10.2217/whe.13.61.
Повний текст джерелаNieder, Carsten, Gro Aandahl, and Astrid Dalhaug. "A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate." Case Reports in Oncological Medicine 2012 (2012): 1–3. http://dx.doi.org/10.1155/2012/537183.
Повний текст джерелаBarnato, Sara E., Jacqueline Sara Jeruss, Kevin P. Bethke, Nora M. Hansen, Seema Ahsan Khan, Jamie H. Von Roenn, Steven T. Rosen, et al. "Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS1134. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1134.
Повний текст джерелаPullela, Srinivas Venkata, Vinod Acharya, Nagarjuna Reddy, Jayvant Harlikar, Amar Kulkarni, Rakesh Chavan, Ajay Yadav, Shuvendu Manna, and Angshuman Ghosh. "Structural corroboration of two important building blocks of the anticancer drug eribulin mesylate through two-dimensional NMR and single-crystal X-ray diffraction studies." Acta Crystallographica Section C Structural Chemistry 72, no. 1 (January 1, 2016): 14–20. http://dx.doi.org/10.1107/s2053229615022305.
Повний текст джерелаNasim, Muhammad Yaser, Ruth Plummer, T. R. Jeffry Evans, Rosemary Morrison, David Alan Anthoney, Sophie Haney, Ayman Madi, et al. "A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 2552. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2552.
Повний текст джерелаIwamoto, Mitsuhiko, Nayuko Sato, Risa Terasawa, Hiroya Fujioka, Yuko Takahashi, Kosei Kimura, Satoru Tanaka, and Kazuhisa Uchiyama. "Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): TPS1140. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps1140.
Повний текст джерелаRaftopoulos, Harry, Joseph Aisner, Kirushna Kumar, Sanjay Goel, Christian Dittrich, Minish Jain, Prashanth Gopalakrishna, Paloma Salazar, Beverley Jones, and Daniel Peter Petrylak. "Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e19145-e19145. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19145.
Повний текст джерелаChiba, Hiroyuki, and Katsuya Tagami. "Research and Development of HALAVEN(Eribulin Mesylate)." Journal of Synthetic Organic Chemistry, Japan 69, no. 5 (2011): 600–610. http://dx.doi.org/10.5059/yukigoseikyokaishi.69.600.
Повний текст джерелаFujimoto, Etsuko, Kazuhiro Takehara, Tamaki Tanaka, Takanori Yokoyama, Katsuyuki Tomono, Mika Okazawa-Sakai, Shinichi Okame, Yoshifumi Sugawara, and Norihiro Teramoto. "Uterine leiomyosarcoma well-controlled with eribulin mesylate." International Cancer Conference Journal 8, no. 1 (November 12, 2018): 33–38. http://dx.doi.org/10.1007/s13691-018-0350-1.
Повний текст джерелаVahdat, Linda T., Agustin Garcia, Charles L. Vogel, Christine M. Pellegrino, Deborah L. Lindquist, Joseph A. Sparano, Prashanth Gopalakrishna, and Nicholas Iannotti. "Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study." Journal of Clinical Oncology 30, no. 27_suppl (September 20, 2012): 121. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.121.
Повний текст джерелаLiu, Liping, Zhe-Yu Hu, Ning Xie, Xiaohong Yang, Huawu Xiao, Jing Li, Can Tian, et al. "Eribulin mesylate versus eribulin plus anlotinib in patients with advanced or metastatic breast cancer: Results of a phase II study." Journal of Clinical Oncology 40, no. 16_suppl (June 1, 2022): 1094. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1094.
Повний текст джерелаSenapati, Sibadatta, and Chepuri V. Ramana. "A concise/catalytic approach for the construction of the C14–C28 fragment of eribulin." Organic & Biomolecular Chemistry 19, no. 20 (2021): 4542–50. http://dx.doi.org/10.1039/d1ob00661d.
Повний текст джерелаGluck, Stefan, Joyce O'Shaughnessy, Kristi McIntyre, Lee Steven Schwartzberg, Sharon Wilks, Shannon Leigh Huggins-Puhalla, Erhan Berrak, James X. Song, David Cox, and Linda T. Vahdat. "Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER+/- locally recurrent or metastatic breast cancer (BC): Results from 2 phase 2, multicenter, single-arm studies." Journal of Clinical Oncology 32, no. 26_suppl (September 10, 2014): 140. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.140.
Повний текст джерелаXie, Xiao-Feng, Jia-Yi Huang, Li-Ping Chen, Xiao-Feng Lan, Qiu-Yi Zhang, Lin Song, Xue Bai, and Cai-Wen Du. "Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report." Journal of International Medical Research 50, no. 7 (July 2022): 030006052210900. http://dx.doi.org/10.1177/03000605221090097.
Повний текст джерелаO'Shaughnessy, Joyce, Shannon Leigh Huggins-Puhalla, Sharon Wilks, Adam Brufsky, Lee Steven Schwartzberg, Erhan Berrak, James X. Song, David Cox, and Linda T. Vahdat. "Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase 2, single-arm, multicenter study." Journal of Clinical Oncology 32, no. 26_suppl (September 10, 2014): 139. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.139.
Повний текст джерелаMoore, M. J., P. Tang, D. Renouf, P. Major, D. Hedley, V. Paterson, L. Wang, B. Dhesy-Thind, B. Southwood, and L. Doyle. "A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e15634-e15634. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15634.
Повний текст джерелаVahdat, Linda T., Brian Pruitt, Carol J. Fabian, Ragene R. Rivera, David A. Smith, Elizabeth Tan-Chiu, Jonathan Wright, et al. "Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane." Journal of Clinical Oncology 27, no. 18 (June 20, 2009): 2954–61. http://dx.doi.org/10.1200/jco.2008.17.7618.
Повний текст джерелаKo, Hyemi, Myungsun Lee, Eunyoung Cha, Jiyoung Sul, Junbeom Park, and Jinsun Lee. "Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation." Medicina 58, no. 4 (April 15, 2022): 547. http://dx.doi.org/10.3390/medicina58040547.
Повний текст джерелаWilks, Sharon, and Kristi Mcintyre. "Case Studies in the Management of Metastatic Breast Cancer with Eribulin." Clinical Medicine Insights: Oncology 9 (January 2015): CMO.S27962. http://dx.doi.org/10.4137/cmo.s27962.
Повний текст джерелаHussar, Daniel A., and Lisa Pasco. "New drugs: Ceftaroline fosamil, pegloticase, and eribulin mesylate." Journal of the American Pharmacists Association 51, no. 2 (March 2011): 316–19. http://dx.doi.org/10.1331/japha.2011.11511.
Повний текст джерелаWitteveen, P., S. Marchetti, M. Mergui-Roelvink, L. Reyderman, W. Copalu, J. Wanders, A. Jenner, G. Edwards, J. H. Schellens, and E. E. Voest. "Eribulin mesylate pharmacokinetics in patients with hepatic impairment." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2582. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.2582.
Повний текст джерелаCigler, Tessa, and Linda T. Vahdat. "Eribulin mesylate for the treatment of breast cancer." Expert Opinion on Pharmacotherapy 11, no. 9 (May 7, 2010): 1587–93. http://dx.doi.org/10.1517/14656566.2010.486790.
Повний текст джерелаNelson, Ariel Ann, Shivaprasad Manjappa, Yuvraj Choudhary, Cheryl L. Thompson, Jeanine Agler, Bethany Lawrence, Manmeet Singh Ahluwalia, and Paula Silverman. "Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e12571-e12571. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e12571.
Повний текст джерелаMiano, Salvatora Tindara, Edoardo Francini, Roberto Petrioli, and Guido Francini. "A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient." Future Oncology 16, no. 1s (January 2020): 33–38. http://dx.doi.org/10.2217/fon-2019-0600.
Повний текст джерелаJansen, M., M. Vernaz-Gris, C. DesJardins, N. Wong, M. Campone, J. Cortes, J. Wanders, D. Shuster, and E. Fuseau. "Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 2524. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.2524.
Повний текст джерелаKok, Victor C. "Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings." Breast Cancer: Basic and Clinical Research 9 (January 2015): BCBCR.S32787. http://dx.doi.org/10.4137/bcbcr.s32787.
Повний текст джерелаCortes, Javier, Linda Vahdat, Joanne L. Blum, Chris Twelves, Mario Campone, Henri Roché, Thomas Bachelot, et al. "Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine." Journal of Clinical Oncology 28, no. 25 (September 1, 2010): 3922–28. http://dx.doi.org/10.1200/jco.2009.25.8467.
Повний текст джерелаSrinivasa, BJ, Bhanu Prakash Lalkota, Girish Badarke, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Mansi Khanderia, et al. "Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience." Clinical Medicine Insights: Oncology 12 (January 1, 2018): 117955491878247. http://dx.doi.org/10.1177/1179554918782475.
Повний текст джерелаChandrasekhar, Srivari, Vikram Gaddam, Lavanya Nadella, Genji Sukumar, and Prathama Mainkar. "Stereoselective Synthesis of Northern Fragment of Eribulin Mesylate from d-Mannose." Synthesis 50, no. 09 (February 21, 2018): 1901–6. http://dx.doi.org/10.1055/s-0036-1591769.
Повний текст джерелаTwelves, Chris, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus, and Peter A. Kaufman. "Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer." Breast Cancer: Basic and Clinical Research 10 (January 2016): BCBCR.S39615. http://dx.doi.org/10.4137/bcbcr.s39615.
Повний текст джерелаXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, and Naoto T. Ueno. "Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines." Biomedicines 11, no. 3 (February 28, 2023): 735. http://dx.doi.org/10.3390/biomedicines11030735.
Повний текст джерелаPatil, S., R. Thippeswamy, HP Shashidara, CT Satheesh, H. Vittal, and S. Mishra. "Eribulin mesylate in Indian patients: A single center experience." Indian Journal of Cancer 52, no. 3 (2015): 297. http://dx.doi.org/10.4103/0019-509x.176735.
Повний текст джерелаSimoneaux, Richard. "Eribulin Mesylate Plus Pembrolizumab Shows Encouraging Efficacy in TNBC." Oncology Times 40 (February 2018): 15–16. http://dx.doi.org/10.1097/01.cot.0000530523.23834.dc.
Повний текст джерелаLee, Hyoseon, Yongseo Park, Heesun Jung, Seong Take Kim, Seunghui Sin, Eunjung Ko, In-Soo Myeong, et al. "Synthesis of the C1–C13 fragment of eribulin mesylate." Tetrahedron 75, no. 33 (August 2019): 4570–76. http://dx.doi.org/10.1016/j.tet.2019.06.050.
Повний текст джерелаNakai, M., M. Suzuki, T. Kurita, K. Yanagihara, and H. Takei. "Eribulin Mesylate improving survival outcomes of metastatic breast cancer." Breast 32 (March 2017): S67. http://dx.doi.org/10.1016/s0960-9776(17)30228-x.
Повний текст джерелаChiba, Hiroyuki, and Katsuya Tagami. "ChemInform Abstract: Research and Development of HALAVEN (Eribulin Mesylate)." ChemInform 42, no. 50 (November 17, 2011): no. http://dx.doi.org/10.1002/chin.201150215.
Повний текст джерелаPapadaki, Maria A., Anastasia Mala, Aikaterini C. Merodoulaki, Maria Vassilakopoulou, Dimitrios Mavroudis, and Sofia Agelaki. "Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate." Cancers 14, no. 16 (August 12, 2022): 3903. http://dx.doi.org/10.3390/cancers14163903.
Повний текст джерелаTremblay, Gabriel, Unnati Majethia, Ilias Kontoudis, and Jesús De Rosendo. "Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy." Journal of Health Economics and Outcomes Research 3, no. 2 (October 21, 2015): 180–93. http://dx.doi.org/10.36469/9834.
Повний текст джерелаSM, Bindu, PL Rema, and Praveen Jacob Ninan. "Eribulin Mesylate in Treated Metastatic Breast Cancer Patients: A Retrospective Study of Tumor Response and Adverse Effects." Galore International Journal of Health Sciences and Research 6, no. 2 (June 15, 2021): 37–44. http://dx.doi.org/10.52403/gijhsr.20210405.
Повний текст джерелаDemetri, George D., Patrick Schöffski, Giovanni Grignani, Jean-Yves Blay, Robert G. Maki, Brian A. Van Tine, Thierry Alcindor, et al. "Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine." Journal of Clinical Oncology 35, no. 30 (October 20, 2017): 3433–39. http://dx.doi.org/10.1200/jco.2016.71.6605.
Повний текст джерелаBlum, J. L., B. Pruitt, C. J. Fabian, R. R. Rivera, D. E. Shuster, N. L. Meneses, K. Chandrawansa, F. Fang, S. Z. Fields, and L. Vahdat. "Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 1034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1034.
Повний текст джерелаAdamo, Vincenzo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, et al. "Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study." Therapeutic Advances in Medical Oncology 11 (January 2019): 175883591989575. http://dx.doi.org/10.1177/1758835919895755.
Повний текст джерелаMcBride, Ali, Claudio Faria, Xuan Li, and Annette Powers. "Eribulin treatment patterns in patients with and without prior anthracycline use." Journal of Clinical Oncology 32, no. 30_suppl (October 20, 2014): 292. http://dx.doi.org/10.1200/jco.2014.32.30_suppl.292.
Повний текст джерелаHensley, M. L., S. Kravetz, C. Sima, W. Tew, L. Pereira, P. Sabbatini, C. Whalen, C. A. Aghajanian, C. Zarwan, and S. Berlin. "Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant epithelial ovarian cancer (PR-EOC): A CTEP-sponsored phase II study." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 5561. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5561.
Повний текст джерелаTraina, Tiffany A., Clifford Hudis, Robert Lehman, Jessicca Rege, Wenquan Wang, David Cox, and Andrew David Seidman. "A phase II, single-arm, feasibility study of dose-dense doxorubicin and cyclophosphamide (AC) followed by eribulin mesylate for the adjuvant treatment of early-stage breast cancer (EBC)." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS1145. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1145.
Повний текст джерелаFilonenko, D. V., and A. V. Belonogov. "ERIBULIN MESYLATE: OUR EXPERIENCE IN A REAL-LIFE CLINICAL SETTING." Malignant tumours 7, no. 4 (January 1, 2017): 21–28. http://dx.doi.org/10.18027/2224-5057-2017-7-4-21-28.
Повний текст джерелаAditya, Suruchi. "Eribulin mesylate: A new therapeutic option for metastatic breast cancer." Journal of Basic and Clinical Reproductive Sciences 2, no. 1 (2013): 6. http://dx.doi.org/10.4103/2278-960x.112571.
Повний текст джерела